Применение мезенхимальных стволовых клеток костного мозга в лечении больных с острой атакой язвенного колита
DOI :
https://doi.org/10.15587/2313-8416.2015.40957Mots-clés :
биологическая терапия, воспалительные заболевания кишечника, мезенхимальные стволовые клетки, язвенный колитRésumé
Цель работы: сравнить результаты лечения двух групп больных с острой атакой язвенного колита, получающих стандартную терапию и терапию с применением культуры аллогенных мезенхимальных стволовых клеток. По результатам проведенной работы установлено, что введение культуры МСК повышает эффективность противовоспалительной терапии у больных с острой атакой ЯК.
Références
Recommendations for the diagnosis and treatment of adult patients with ulcerative colitis (2013). Proctology, 3 (45), 4–38.
Pershko, A. M., Samedov, B. H., Rukshin, O. A. (2003). Ulcerative colitis: diagnosis and treatment. St. Petersburg, 112.
Sadler, R. S. (1994). Epidemiology of inflammatory bowel disease. Inflammatory bowel disease: From bench to bedside. Baltimore, Williams and Wilkins, 5–30.
Amosy E. M’Koma. Inflammatory Bowel Disease: An Expanding Global Health Problem. Clinical Medicine Insights: Gastroenterology 2013:6 33–47. doi: 10.4137/cgast.s12731
Belousova, E. A., Nikitina, N. V., Tsodikova, O. M. (2013). Treatment of ulcerative colitis mild and moderate flow. Farmateka, 2, 42–46.
Khalif, I. L. (2006). Medical Management of ulcerative colitis. Russian Journal of Gastroenterology, Hepatology, Coloproctology, 16 (3), 58–62.
Khalif, I. L. (2006). Principles of treatment of ulcerative colitis (recommendations of the Russian group to study inflammatory bowel disease). Proctology, 2, 31–33.
Dignass, A., Lindsay, J. O., Sturm, A., Windsor, A., Colombel, J.-F., Allez, M. et. al. (2012). Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management. Journal of Crohn’s and Colitis, 6 (10), 991–1030. doi: 10.1016/j.crohns.2012.09.002
Langholz, E., Munkholm, P., Davidsen, M., Binder, V. (1994). Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology, 107, 3–11.
Michelassi, F., Fichera, A.; Kirshner, J. B. (Еd.) (2000). Inflammatory Bowel Disease. 5-th edition. Philadelphia, 616–626.
Vorobiev, G. I., Khalif, I. L. (2008). Inflammatory bowel disease. Moscow: Miklos, 400.
Knyazev, O. V., Churikova, A. A. (2014). Anticytokine therapy and quality of life in patients with inflammatory bowel disease. Evidence gastroenterology, 2, 17–23.
Farkas, K., Lakatos, P. L., Nagy, F., Szepes, Z., Miheller, P., Papp, M. et. al. (2013). Predictors of relapse in patients with ulcerative colitis in remission after one-year of infliximab therapy. Scandinavian Journal of Gastroenterology, 48 (12), 1394–1398. doi: 10.3109/00365521.2013.845906
Zhang, Q., Shi, S., Liu, Y., Uyanne, J., Shi, Y., Shi, S., Le, A. D. (2009). Mesenchymal Stem Cells Derived from Human Gingiva Are Capable of Immunomodulatory Functions and Ameliorate Inflammation-Related Tissue Destruction in Experimental Colitis. The Journal of Immunology, 183 (12), 7787–7798. doi: 10.4049/jimmunol.0902318
Knyazev, O. V., Parfenov, A. I., Shcherbakov, P. L., Ruchkina, I. N., Konoplyannikov, A. G. (2013). Cell therapy for refractory Crohn's disease. Cell technologies in biology and medicine, 3, 145–152.
Ciccocioppo, R., Bernardo, M. E., Sgarella, A. et al. (2011). Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn’s disease. Gut, 60 (6), 788–798. doi: 10.1136/gut.2010.214841
Lalu, M. M., McIntyre, L., Pugliese, C., Fergusson, D., Winston, B. W., Marshall, J. C. et. al. (2012). Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical Trials. PLoS ONE, 7 (10), e47559. doi: 10.1371/journal.pone.0047559
Van Deen, W. K., Oikonomopoulos, A., Hommes, D. W. (2013). Stem cell therapy in inflammatory bowel disease. Current Opinion in Gastroenterology, 29 (4), 384–390. doi: 10.1097/mog.0b013e328361f763
Belousova, E. A. (2002). Ulcerative colitis and Crohn's disease. Tver: Triad, 128.
Recommendations for the diagnosis and treatment of adult patients with ulcerative colitis (2013). Proctology, 3 (45), 4–38.
D’Haens, G., Sandborn, W. J., Feagan, B. G., Geboes, K., Hanauer, S. B., Irvine, E. J. (2007). A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis. Gastroenterology, 132 (2), 763–786. doi: 10.1053/j.gastro.2006.12.038
Rachmilewitz, D. (1989). Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ, 298 (6666), 82–86. doi: 10.1136/bmj.298.6666.82
Sadler, R. S. (1994). Epidemiology of inflammatory bowel disease. Inflammatory bowel disease: From bench to bedside. Baltimore, Williams and Wilkins, 5–30.
Tsyb, A. F., Konoplyannikov, A. G., Kolesnikov, A. I. et al. (2004). The preparation and use in medicine cell cultures of mesenchymal stem cells in human bone marrow. Bulletin of the Russian Academy of Medical Sciences, 59 (9), 71–76.
Ferrante, M., Vermeire, S., Katsanos, K. H., Noman, M., Van Assche, G., Schnitzler, F. (2007). Predictors of early response to infliximab in patients with ulcerative colitis. Inflammatory Bowel Diseases, 13 (2), 123–128. doi: 10.1002/ibd.20054
Oyama, Y., Traynor, A. E., Barr, W., Burt, R. K. (2003). Allogeneic stem cell transplantation for autoimmune diseases: nonmyeloablative conditioning regimens. Bone Marrow Transplant, 32, S81–S83. doi: 10.1038/sj.bmt.1703950
Téléchargements
Publié-e
Numéro
Rubrique
Licence
(c) Tous droits réservés Олег Владимирович Князев, Анна Валерьевна Каграманова, Оксана Николаевна Болдырева, Нина Александровна Фадеева, Елена Юрьевна Жулина, Екатерина Михайловна Мясникова, Петр Леонидович Щербаков, Анатолий Георгиевич Коноплянников, Альбина Александровна Лищинская, Ирина Николаевна Ручкина, Асфольд Иванович Парфенов 2015
Cette œuvre est sous licence Creative Commons Attribution 4.0 International.
Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.
Authors, who are published in this journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
